Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia

BACKGROUND: Acute myeloid leukemia (AML) is a common hematological malignancy. Gemtuzumab ozogamicin (GO), a humanized anti-CD33 antibody conjugated with the potent anti-tumor antibiotic calicheamicin, represents a promising targeted therapy for AML. Annexin A5 (ANXA5) is a proposed marker for the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Nan, Zhang, Ying, Zhang, Ping, Lou, Shifeng, Chen, Ying, Li, Huan, Zeng, Hanqing, Shen, Yan, Deng, Jianchuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310896/
https://www.ncbi.nlm.nih.gov/pubmed/32636939
http://dx.doi.org/10.1177/1758835920927635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310896/
https://www.ncbi.nlm.nih.gov/pubmed/32636939
http://dx.doi.org/10.1177/1758835920927635

Ejemplares similares